Share Name Share Symbol Market Type Share ISIN Share Description
Immupharma LSE:IMM London Ordinary Share GB0033711010 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.125p +0.27% 46.50p 46.00p 47.00p 47.00p 46.25p 46.25p 103,325.00 16:35:14
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.1 -4.5 -4.4 - 56.63

Immupharma Share Discussion Threads

Showing 7126 to 7149 of 7150 messages
Chat Pages: 286  285  284  283  282  281  280  279  278  277  276  275  Older
DateSubjectAuthorDiscuss
24/1/2017
19:15
It was in proactive investor,
barriew
24/1/2017
18:09
barriew - Oh OK please ignore then. Says published today. I know the article has been published before on Proactive Investors' website but I hadn't seen in in the Daily Mail, must have missed it.
bermudashorts
24/1/2017
17:29
Thats a old link, it was released around xmas,
barriew
24/1/2017
17:19
Courtesy of Ivy on LSE hXXp://www.thisismoney.co.uk/money/investing/article-4152394/SMALL-CAP-IDEAS-pharma-companies-eye-on.html
bermudashorts
24/1/2017
16:00
I agree, longshanks. As for the size of the retracement, if you look at the chart it is smaller in percentage terms than the previous two retracements after a spike. I said we would see 46p again before forming another pennant in the range between 46p and 55p approx and then start our move northwards again. Its normal for Lanstead to take advantage of the spike but they are not overdoing it. Yes, they have had a bearing on the share price but they have had a bearing on the smooth progress of P3 too ....... by funding it !
luminoso
24/1/2017
10:59
May I suggest you take a chill pill bookbroker.Prices ebb and flow - there is no real reason to worry as far as I can tell. The market will find its balance.We are in p3 with results due in 11 months time. Prices will change for sure with those results but you can't demand that other investors buy in at a higher price than that paid by you just because you want it.Nor can you demand the BoD make decisions to meet your short term priorities. I am sure that license/distribution deals are being discussed and negotiated. The timing of any decision won't be just to give the share price an immediate boost; it will be because all details have been addressed and the BoD have assessed it to be the best deal.
longshanks
24/1/2017
10:47
I think Lanstead is having a bearing on the price, they fund their involvement by being realising their investment most likely through hedges and trading of the stock to profit from the investment!
bookbroker
24/1/2017
10:44
Anyone seen the Northland Buy Note this morning?
glennrcharles
24/1/2017
10:38
The Market can remain irrational, much longer than you can remain solvent.
pj 1
24/1/2017
10:36
I'm surprised by the size of retracement, could there be case of keeping the value at around these levels and then getting in sub £1 even after p111 results.The gamble of an investment is removed with still substantial risk free upside.We all see various stocks artificially manipulated.Or is it the case that the market just does not see a sizeable deal coming even after positive p111.But having re watched the June 2016 presentation the scope for this peptide seems to me to be amazing ,which just makes me baffled by the current valuation "any thoughts"
best1467
24/1/2017
10:13
My impression is that during 2014 - 2016 that they were 'greedy' re doing a deal. They wanted something at least as good as Cephalon, but found potential partners playing hard ball. A potential partner will come about (IMO) but they equally might wait till the drug is further derisked. Phase 3 (or at least this part of it) is not without risks and about 30% of drugs that go into phase 3 fail to meet endpoints. Edit: In terms of placings, not sure needed with the Lanstead deal, and while they run a very tight ship financially, IF they did raise, it would be to progress other indications or Nucant. A discussion we had on here last week I think. Personally, I'm happy to let my investment here run until we get results/deal. Downside maybe 50% but upside 10 x + Decent risk reward.
waterloo01
24/1/2017
10:13
A placing is a possibility, the movement ok to the news of the completion of trial numbers moved the stock, however twenty five per cent was a big news, maybe they have already raised some cash, do not know how the agreement works with Landstead as regards further cash raising1
bookbroker
24/1/2017
10:10
And yes I appreciate the progress made, and the performance of the stock over the last twelve months, but on a longer timescale relative to the progress this has been regressive!
bookbroker
24/1/2017
10:09
Is the appointment of Northland an omen of the next placing?
pj 1
24/1/2017
10:08
I have been here since 2012, that's is my issue, I was an investor in Alizyme, maybe you need to do your research, I have increased the holding a fair bit and reduced over time, and back again, my issue is that when a drug trial reaches P111 it is pretty much a given that the efficacy is strong enough to achieve a positive outcome, barring a significant setback in terms of reaction to the dosage and tolerance levels by the recipients, my gripe is that with the few alternatives to this treatment as regards actual drugs for lupus I would have expected the board to have pursued a partnership to replace Cephalon, taking into account the risks and the need for future funding for their other projects!
bookbroker
24/1/2017
09:56
Obviously bookbroker is new to IMM. He hasn't sat through the many volatile share price movements that defy logic over the last few years. It's an illiquid counter for the most part, with a solid II base and a relatively small PI base. I expect we will get more of the same right up to FDA decision timer, so bookbroker better get used to it or sell out.
divmad
24/1/2017
09:43
What's your issue with McCarthy? As for the SP, it's done rather well in 2016, but sure there is a gap between current value and potential value. It's the risk that the drugs don't work, or work as well as hoped for, plus uncertainty as to needing further trials. Northland as NOMAD is probably better than Panmure.
waterloo01
23/1/2017
11:25
I tend to see McCarthy as the gaffer, as he seems to be the spokesperson at most of the reports released!
bookbroker
23/1/2017
11:00
Bookbroker, I believe McCarthy is non-exec Chairman, not CEO. CEO is the strangely silent Dimitri Dimitriou. Let's hope he's doing inspiring things behind the scenes.
spacehorse
23/1/2017
10:54
I would like to see another institution on board, currently the major shareholder is still Zimmer, and some other early stage individuals, but I am slightly bemused that this co. Does not carry a higher valuation purely on the basis of progress made in the last four years, for God's Sake we are trading way lower than 2012, for me that is a conundrum!
bookbroker
23/1/2017
10:45
gclark Lanstead announce dealings retrospectively, while they dribble shares on to the market. Last time they declared going through three thresholds over a fair period of time. They will ease off and allow the share price to move up, IMO. It all seems very orderly, but its not going to be a quick buck for us, thats for sure ! There is always the chance that they will offload to another institution as they did once last year, and that would release the brakes on our share price rise.
luminoso
23/1/2017
10:28
Surely this co. can do better than raising cash through Lanstead Capital, why do they not pursue a listing on the Nasdaq, McCarthy should see the long term benefits of that direction, but then his track record is pretty patchy, so I am not surprised where we are, he is a very uninspiring CEO!
bookbroker
21/1/2017
10:02
However I still believe they should be involving other pharmas at this stage!
bookbroker
21/1/2017
10:00
More likely, it's going to ebb and flow this co., had a decent rise on recent news, Landstead's involvement suggests a wee bit of volatility, I like to see some more stable outside funding come in though, they seem overly dependent on Landstead, although I appreciate there are other sources looking at the last report!
bookbroker
Chat Pages: 286  285  284  283  282  281  280  279  278  277  276  275  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20170125 01:27:32